Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
NEWARK, Calif., Feb. 07, 2018 --
Depomed, Inc. (NASDAQ:DEPO) today announced that members of senior management will participate in fireside chats at the following healthcare conferences during the month of February.
LEERINK Partners 7th Annual Global Healthcare Conference
Date: Wednesday, February 14, 2018
Time: 2:00 p.m. EST
Location: New York, New York
RBC Capital Markets 2018 Global Healthcare Conference
Date: Thursday, February 22, 2018
Time: 11:30 a.m. EST
Location: New York, New York
The fireside chats will be webcast live and may be accessed via the Investor Relations’ page of the Depomed website at www.depomed.com. A recording of these events will be archived for 30 days on the company's website.
About Depomed
Depomed is a leading specialty pharmaceutical company committed to putting the Patient First in everything it does. Depomed is focused on enhancing the lives of patients, families, physicians, providers and payors through the commercialization of products in the areas of pain and neurology, and in the development of drugs in areas of unmet medical need. Depomed currently markets three medicines focused on neuropathic pain and migraine through its Neurology and Pain businesses and its emerging Specialty Business is focused on orphan drug indications and areas of unmet medical need. To learn more about Depomed, visit www.depomed.com.
Investor Contact:
Christopher Keenan
VP, Investor Relations and Corporate Communications
510-744-8000
[email protected]
